Understanding the adverse effects of ocriplasmin.
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri.
David C
DC
Beebe
D001766:Blindness / Q000139:chemically induced*; D004596:Electroretinography; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D005341:Fibrinolysin / Q000009:adverse effects*; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006801:Humans; D010446:Peptide Fragments / Q000009:adverse effects*; D012160:Retina / Q000187:drug effects*; D012164:Retinal Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D014786:Vision Disorders / Q000139:chemically induced*; D014822:Vitreous Body / Q000187:drug effects*
D005343:Fibrinolytic Agents; D010446:Peptide Fragments; D005341:Fibrinolysin